We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Settles With Purchasers for $94 Million Over Celebrex Pay-For-Delay Deal
Pfizer Settles With Purchasers for $94 Million Over Celebrex Pay-For-Delay Deal
Pfizer reached a $94 million settlement with a class of direct purchasers over claims it used fraudulent patents to keep generic competition off the market for its anti-inflammatory drug Celebrex.